a) The Spiration (Spiration, Inc. , Redmond, WA, USA) device

Slides:

Advertisements

Similar presentations

Quit rate (7-day point prevalence) for long-term nicotine replacement therapy users in the varenicline and placebo groups from weeks 2 to 52, verified.

Advertisements

Summary findings regarding the efficacy/safety profile across xanthines in chronic obstructive pulmonary disease patients. a) Combined plot of the change.

Flow diagram of the systematic research method for detecting matching microRNAs (miRNAs) in systemic sclerosis (SSc) and idiopathic pulmonary fibrosis.

The intermittent hypoxia model in normal volunteers.

Immunostaining for lipid peroxidation product 4-hydroxy-2-nonenal (4-HNE) adduct in the lungs of smokers with and without chronic obstructive pulmonary.

In chronic haemorrhage a) several pigmented macrophages fill the alveoli with dense fibrosis of the interstitium; b) the haemosiderin pigment in macrophages.

Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.

Schematic representation of breathing levels during positive expiratory pressure in an obstructed patient. Schematic representation of breathing levels.

Changes of a) spirometric, plethysmographic, and b) impedance data at 5 Hz induced by bronchodilator in flow limited (□) and nonflow limited (▓) patients.

Single limb “non-vented” respiratory circuit with an exhalation valve (V) sited at a) the distal end of the inspiratory circuit or b) at the end of a short.

Examples of single limb “vented” circuits.

The distribution of the extent of change in inspiratory capacity (IC) during exercise is shown in moderate-to-severe chronic obstructive pulmonary disease.

Representative diaphragm electromyogram (EMG) tracings at rest (a and b) and during maximum voluntary ventilation (c and d) in a healthy subject (a and.

Schematic representations of alveolar units a) in health and b) in chronic obstructive pulmonary disease (COPD), and their corresponding flow versus volume.

Changes in operating lung volumes are shown as ventilation increases with exercise in a) age-matched normal subjects (n = 25) and b) chronic obstructive.

Sensitivity analysis describing the features of the lymphatic control on pleural liquid volume. Sensitivity analysis describing the features of the lymphatic.

Effect of inspiratory rate on respirable particles generated from different inhalation devices. ———: budesonide Turbuhaler® (AstraZeneca, Draco, Sweden;

A) Healthcare utilisation, b) short form (SF)-12 scores and c) work productivity and activity impairment in patients with asthma (▓) and diabetes (▪) in.

Nonspecific interstitial pneumonia fibrosing pattern in a case of connective tissue disease. a) The alveolar walls are thickened by interstitial fibrosis.

Prevalence of chronic bronchitis in relation to active smoking, stratified by age. □: nonsmokers; ▒: 1–10 cigarettes per day; ░: 11–20 cigarettes per day;

Change in transpulmonary pressure (PL) from passive to active breathing during a) volume control ventilation (VCV) and b) pressure control ventilation.

Diagnostic imaging of distal chronic thromboembolic pulmonary hypertension lesions. a) Ventilation/perfusion scintigraphy. b) Conventional pulmonary angiography.

Positron emission tomography scan in the axial plane performed in June 2007 showing intense and homogeneous increased uptake of 18-fluorodeoxyglucose within.

Profile of Pseudomonas aeruginosa resistance by country and antibiotic

A summary of the pathogenesis, pathophysiology and clinical implications of the pulmonary vascular and cardiac abnormalities in interstitial lung disease.

a) Central sleep apnoea.

The projected numbers of tobacco-related deaths between 2000–2035 in millions for a) the world and b) medium- and low-income countries (top) and high-income.

Post-bronchodilator forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) ratio in subjects aged >50 yrs. Post-bronchodilator forced expiratory.

The changing distribution of endothelin (ET)A and ETB subtypes with decreasing vessel diameter. a) ET-1 binding and b) distribution of ETA and ETB receptors.

Neuromechanical coupling was measured in a subset of patients and expressed as tidal volume (VT) divided by the amplitude of the inspiratory pressure swing.

Forest plot meta-analysis of the impact of long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations on changes in.

A) Cumulative count and b) percent cumulative use of the different pulmonary function test (PFT) measures as longitudinal outcomes for systemic sclerosis-associated.

Bronchial thermoplasty procedure

Survival in patients with pulmonary arterial hypertension based on aetiology. •: congenital heart disease; ▪: collagen vascular disease; ▵: HIV-related;

A) Measurement of the right atrial a) area and b) long axis for calculation of right atrial volume. c) Measurement of the left ventricular eccentricity.

Pressure (P)–volume (V) relationships of the total respiratory system a) in normal and b) in chronic obstructive pulmonary disease (COPD). Pressure (P)–volume.

A) Pressure–time and b) flow–time waveforms in the panel of ventilator Astral 150 (ResMed, Bella Vista, Australia). a) The expiratory flow curve does not.

Recordings of quiet tidal breathing at rest, followed by maximal expiration then inspiration. Recordings of quiet tidal breathing at rest, followed by.

Outline of the distal lung regions in haematoxylin and eosin-stained lung tissue [115, 116] showing the inner airway wall (green arrowheads), smooth muscle.

Representative images of computed tomography (CT) scans in patients with small airways disease. a) An inspiratory CT scan in a patient with hypersensitivity.

A) 8-isoprostane levels in exhaled breath condensate in smokers with chronic obstructive pulmonary disease (COPD). *: p

Impact of dose adjustment in case of adverse drug reaction (ADR; includes dose interruption and/or reduction). a) No dose adjustment and b) dose adjustment.

In a representative chronic heart failure patient, tidal flow-volume loops at rest (solid line) and at the peak of symptom-limited incremental exercise.

Overall forest plot from meta-analysis carried out in 11 studies a) assessing the relative risk of adverse events; and subgroup analysis performed on studies.

Representative pressure tracings of a) pulmonary arterial pressure and b) pulmonary arterial wedge pressure (PAWP). Representative pressure tracings of.

The “route to quit” model, which indicates the contribution of different ways of quitting to overall rates of smoking cessation. #: in most cases nicotine.

Relationship between a) forced expiratory flow at 25–75% of forced vital capacity (FVC) (FEF25–75%) and b) forced expiratory flow at 75% of FVC (FEF75%)

Proportion of participants with access to a, b) a radiologist and c, d) a pathologist experienced in interstitial lung diseases to discuss cases of suspected.

Cumulative mortality over 60 months in patients with α1-antitrypsin deficiency and an initial forced expiratory volume in 1 s

A) Inspiratory capacity (IC) in asthmatics with (n=13) and without (n=7) expiratory flow limitation (EFL) at various levels of exercise, expressed as a.

A) Annual diagnosed incidence of pulmonary embolism (PE), and b) annual full incidence of chronic thromboembolic pulmonary hypertension (CTEPH) per 100 000.

A) Tidal volume (VT) (presented as % predicted of vital capacity (VC)), b) breathing frequency (Fb), c) dynamic inspiratory capacity (IC) and d) inspiratory.

Effect of omalizumab (n = 209) on a) clinically significant and b) severe exacerbation rates, compared with placebo (n = 210). #: adjustment due to a pre-study.

Correlation between inspiratory capacity (IC)/total lung capacity (TLC) ratio and oxygen pulse at peak exercise in chronic obstructive pulmonary disease.

Survival rates in older (>65 years) compared with younger (18–65 years) patients with idiopathic pulmonary arterial hypertension. a) Expected ( )

Flow, esophageal pressure, airway pressure, and transpulmonary pressure can be used to calculate respiratory system compliance, chest-wall compliance,

Risk ratio (RR) and number needed to treat (NNT) are time-dependent measures. a) When an intervention is associated with constant relative risk reduction.

A) Operating lung volumes and b) breathing frequency (Fb) during incremental cycle exercise in patients with moderate chronic obstructive pulmonary disease.

Common venovenous extracorporeal membrane oxygen configurations

24-h blood pressure profile after a, d) one night of intermittent hypoxia (IH) exposure, b, e) 13 nights IH exposure and c, f) 5 days after cessation of.

Pulmonary artery pressure in a) healthy subjects and b) pulmonary hypertension (PH) subjects. Pulmonary artery pressure in a) healthy subjects and b) pulmonary.

Trends of mortality rates in the USA between 1930 and 2000 in males according to cancer site. –––––: stomach; ·······: prostate; –– –– ––: colon and rectum;

Mean change from baseline in percentage predicted forced vital capacity (FVC) in the a) phase III CAPACITY [27] and b) ASCEND [14] studies. #: n=174; ¶:

Drugs that target the prostacyclin pathway and their routes of administration. #: approved only by the US Food and Drug Administration; ¶: approved only.

Flow–volume loops of test breaths and preceding control breaths of a representative chronic obstructive pulmonary disease patient with different degrees.

Depiction of an expiratory flow curve.

Flow–volume loops of test breaths and preceding control breaths of three representative chronic obstructive pulmonary disease patients with different degrees.

Nanomaterial-based sensors as a volatolomic analytical platform: simplified working mechanisms. Nanomaterial-based sensors as a volatolomic analytical.

For inspiratory load compensation testing, this threshold positive expiratory pressure (PEP) training device was inverted and connected to a respiratory.

Tracing of tidal breathing followed by an inspiratory manoeuvre to total lung capacity (TLC) to record inspiratory capacity (IC), followed by a full expiration.

Presentation transcript:

a) The Spiration (Spiration, Inc. , Redmond, WA, USA) device a) The Spiration (Spiration, Inc., Redmond, WA, USA) device. b) The device is arranged so that the convex surface is positioned distally, with the aim of allowing expiratory but not inspiratory flow. a) The Spiration (Spiration, Inc., Redmond, WA, USA) device. b) The device is arranged so that the convex surface is positioned distally, with the aim of allowing expiratory but not inspiratory flow. M. I. Polkey, and N. S. Hopkinson Eur Respir Rev 2006;15:99-103 ©2006 by European Respiratory Society